Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
View: Text | PDF
Research Article AIDS/HIV Immunology Infectious disease

T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal

  • Text
  • PDF
Abstract

Early antiretroviral therapy (ART) limits viral reservoir establishment in infants but also constrains virus-specific immunity required to clear reactivated cells. In the early ART context, we evaluated whether combining adeno-associated virus serotype 9–vectored (AAV9-vectored) eCD4-IgG1 with pharmacological latency reversal using the second mitochondria-derived activator of caspases (SMAC) mimetic AZD5582 could promote reservoir reduction and control in SIV-infected infant macaques. AAV9 delivery achieved sustained eCD4-IgG1 expression, and AZD5582 induced on-ART viremia, but the combination did not reduce intact SIV proviral DNA relative to controls. Partial postintervention control of viremia during analytical treatment interruption (ATI) occurred in 2 of 6 infants receiving AAV9-eCD4-IgG1 plus AZD5582 with restricted reservoir expansion during recrudescence at week 13. Intact reservoir size during ATI correlated inversely with on-ART viremia during AZD5582 treatment. Animals were classified as controllers or non-controllers. Controllers did not show increased eCD4-IgG1 expression nor increased on-ART viremia during AZD5582 treatment but harbored less pre-ART intact SIV DNA in PBMCs than non-controllers. Controllers also exhibited higher frequencies and greater polyfunctionality of virus-specific CD8+ T cells prior to ATI. These findings suggest immune control of reservoir size and post-ART viral dynamics in early-treated infants and that AAV9-eCD4-IgG1 plus AZD5582 increases the likelihood of post-ART viral control.

Authors

Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi

×

Figure 3

AZD5582 induces latency reversal in infant macaques during suppressive ART.

Options: View larger image (or click on image) Download as PowerPoint
AZD5582 induces latency reversal in infant macaques during suppressive A...
(A) Longitudinal ultrasensitive plasma viremia in AZD5582-treated intervention (n = 10) and control (n = 10) infant macaques over weeks relative to the first AZD5582 dose (vertical red line). Plasma viral load is plotted on a log10 scale. Solid blue and orange lines indicate group means for intervention and control animals, respectively, with corresponding shaded areas indicating ± SEM. The dotted horizontal line denotes the assay limit of detection (3 copies/mL). (B) Per-animal geometric mean ultrasensitive plasma viremia across AZD5582-phase time points from baseline through week 7. Each symbol represents an individual animal; groups were compared using a 2-tailed Mann-Whitney U test. (C) Week-by-week fold difference in on-ART viremia between intervention and control groups. Symbols indicate ratios of geometric mean viral loads, with 95% CIs derived from Welch’s unequal-variance t test on ln-transformed values and back-transformed to the ratio scale; consequently, CIs are asymmetric around the point estimates. Values above the dotted horizontal line at y = 1 indicate higher viremia in the intervention group, consistent with latency reversal. Time points with P < 0.05 are indicated.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts